Scientists at Johns Hopkins Meet the Moment with a Saliva-Based Serological Assay for COVID-19

Technology You Trust, Versatility You Want

INTELLIFLEX builds on the proven performance of xMAP® Technology to empower research

Our Research and Development (R&D), Manufacturing, and Launch Readiness Teams worked tirelessly to develop and launch the newest platform in our xMAP® Technology family—xMAP® INTELLIFLEX.

This innovative platform has exciting new features, which support low- and high-plex capabilities, offer a broad dynamic range, and quickly deliver reliable results. Additionally, INTELLIFLEX empowers users to acquire data about two parameters per target protein or nucleic acid with its new dual reporter capability, saving time and generating more data with fewer samples. Researchers are excited about this new functionality, and early access customers have successfully completed preliminary studies on pre-commercial units.

Studio setup for virtual Field Service training.

Stephen Angeloni, PhD, Senior Field Application Scientist, LTG, works with INTELLIFLEX in a Rochester University lab.

The teams responsible for getting INTELLIFLEX ready had to do a lot of shifting in the pandemic

Many teams at Luminex, particularly R&D and Manufacturing, have continued to work on-site to design and build units and reagents for the INTELLIFLEX Platform. Other teams have gone remote, with our Sales and Support Teams doing training online with subject matter experts at our flagship office in Austin, due to pandemic-related travel restrictions. Even with all of the shifting, bringing xMAP INTELLIFLEX Systems to market has been a rewarding experience for us at Luminex. As the latest in the family of xMAP Systems, INTELLIFLEX provides a solution that can fit the needs of every research lab.

To learn more about xMAP INTELLIFLEX Systems, check out this recent presentation to hear about some of the exciting applications made possible by this new platform.

First fully remote Field Service training in the Netherlands.

David Rocha, Technical Product Manager, receives units for Field Service training.

Gabby Mora, Associate Product Manager, xMAP, provided sales training with live virtual demos.

The same xMAP® Technology you love, now designed to do more.

xMAP® INTELLIFLEX is the first xMAP multiplexing platform that combines low- and high-plex capabilities, quick time to results, and the ability to get double the data per analyte with its new dual reporter capability.

It’s worth getting xCITED about.

Learn more at luminexcorp.com/INTELLIFLEX.

For Research Use Only. Not for use in diagnostic procedures. ©2021 Luminex Corporation. All Rights reserved. Luminex and xMAP are trademarks of Luminex Corporation, registered in the US and other countries. xMAP INTELLIFLEX is a trademark of Luminex Corporation.

xMAP® INTELLIFLEX Takes Flight COVID-19 antibody responses are complex. Profiling them shouldn’t be.

The first xMAP® INTELLIFLEX System traveled from Luminex’s headquarters in Austin, Texas and was installed at the Natural and Medical Science Institute (NMI) in Reutlingen, Germany by Rob Wilkens, Technical Service Supervisor, and Wilco de Jager, Senior Field Applications Scientist.

Luminex Corporation, Austin

xMAP® INTELLIFLEX units ready to ship!

Natural and Medical Sciences Institute (NMI) Reutlingen, Germany

Wilco de Jager and Rob Wilkens Set up and ready to go in the NMI lab!

Wilco de Jager and Rob Wilkens

The newest generation of xMAP® Technology has arrived!

Technology you trust.

Versatility you want. Built on the proven performance of xMAP Technology, xMAP INTELLIFLEX is a modern, flow-based platform built to enhance performance and simplify the user experience.

xMAP® Technology by the Numbers

16,000+

instruments placed

1,300

RUO kits

54,000+

peer-reviewed publications

100+

510(k) clearances

80+

countries

70+

partners

#ScienceForward

Detect N, RBD, S1, and S2 antibodies simultaneously

Profile the humoral response to COVID-19 infection or vaccination with Bio-Plex Pro SARS-CoV-2 Serology Assays. Choose from IgG, IgM, or IgA-specific panels for highly sensitive and specific detection of antibodies against SARS-CoV-2 nuleocapsid protein and spike protein subunits (receptor binding domain, spike 1, and spike 2). For research use only. Not for use in diagnostic procedures.